GB9917012D0 - Combined preparations comprising antitumor agents - Google Patents

Combined preparations comprising antitumor agents

Info

Publication number: GB9917012D0
Authority: GB; United Kingdom
Prior art keywords: antitumor agents; combined preparations; preparations; combined; antitumor
Prior art date: 1999-07-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB9917012.8A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Italia SRL

Original Assignee

Pharmacia and Upjohn SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-20

Filing date

1999-07-20

Publication date

1999-09-22

1999-07-20 Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA

1999-07-20 Priority to GBGB9917012.8A priority Critical patent/GB9917012D0/en

1999-09-22 Publication of GB9917012D0 publication Critical patent/GB9917012D0/en

2000-07-10 Priority to PCT/EP2000/006540 priority patent/WO2001005425A2/en

2000-07-10 Priority to JP2001510479A priority patent/JP2003504413A/en

2000-07-10 Priority to AU59839/00A priority patent/AU5983900A/en

2000-07-10 Priority to EP00945903A priority patent/EP1200098A2/en

Status Ceased legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GBGB9917012.8A 1999-07-20 1999-07-20 Combined preparations comprising antitumor agents Ceased GB9917012D0 (en)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
GBGB9917012.8A GB9917012D0 (en)	1999-07-20	1999-07-20	Combined preparations comprising antitumor agents
PCT/EP2000/006540 WO2001005425A2 (en)	1999-07-20	2000-07-10	Combined preparations comprising daunorubicin derivatives and her2 antibodies
JP2001510479A JP2003504413A (en)	1999-07-20	2000-07-10	Combination preparation containing an antitumor substance
AU59839/00A AU5983900A (en)	1999-07-20	2000-07-10	Combined preparations comprising antitumor agents
EP00945903A EP1200098A2 (en)	1999-07-20	2000-07-10	Combined preparations comprising daunorubicin derivatives and anti her2 antibodies

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9917012.8A GB9917012D0 (en)	1999-07-20	1999-07-20	Combined preparations comprising antitumor agents

Publications (1)

Publication Number	Publication Date
GB9917012D0 true GB9917012D0 (en)	1999-09-22

Family

ID=10857596

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB9917012.8A Ceased GB9917012D0 (en)	1999-07-20	1999-07-20	Combined preparations comprising antitumor agents

Country Status (5)

Country	Link
EP (1)	EP1200098A2 (en)
JP (1)	JP2003504413A (en)
AU (1)	AU5983900A (en)
GB (1)	GB9917012D0 (en)
WO (1)	WO2001005425A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1282443B1 (en)	2000-05-19	2009-09-02	Genentech, Inc.	Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
GB0114654D0 (en) *	2001-06-15	2001-08-08	Pharmacia & Upjohn Spa	Anti-tumor compound
UA94899C2 (en)	2005-01-21	2011-06-25	Дженентек, Инк.	Fixed dosing of her antibodies
EP1850874B1 (en)	2005-02-23	2013-10-16	Genentech, Inc.	Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
EP2132573B1 (en)	2007-03-02	2014-04-23	Genentech, Inc.	Predicting response to a her dimerisation inhbitor based on low her3 expression
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
DK2171090T3 (en)	2007-06-08	2013-06-10	Genentech Inc	Gene expression markers for tumor resistance to HER2 inhibitor therapy
BRPI0812682A2 (en)	2008-06-16	2010-06-22	Genentech Inc	metastatic breast cancer treatment
ES2572728T3 (en)	2009-03-20	2016-06-02	F. Hoffmann-La Roche Ag	Bispecific anti-HER antibodies
CA2761280A1 (en)	2009-05-29	2010-12-02	F. Hoffmann-La Roche Ag	Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (en)	2010-02-18	2016-12-21	基因泰克公司	Neuregulin antagonist and the purposes in treatment cancer thereof
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
WO2012069466A1 (en)	2010-11-24	2012-05-31	Novartis Ag	Multispecific molecules
JP5766296B2 (en)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
MX2014001766A (en)	2011-08-17	2014-05-01	Genentech Inc	Neuregulin antibodies and uses thereof.
WO2013063229A1 (en)	2011-10-25	2013-05-02	The Regents Of The University Of Michigan	Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CN106987620A (en)	2011-11-30	2017-07-28	霍夫曼-拉罗奇有限公司	Erbb3 mutation in cancer
WO2013083810A1 (en)	2011-12-09	2013-06-13	F. Hoffmann-La Roche Ag	Identification of non-responders to her2 inhibitors
JP2015514710A (en)	2012-03-27	2015-05-21	ジェネンテック，インコーポレイテッド	Diagnosis and treatment of HER3 inhibitors
WO2014083178A1 (en)	2012-11-30	2014-06-05	F. Hoffmann-La Roche Ag	Identification of patients in need of pd-l1 inhibitor cotherapy
US20190151346A1 (en)	2016-05-10	2019-05-23	INSERM (Institute National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
US10167342B2 (en)	2016-08-29	2019-01-01	Fazel Shokri	Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
PT110526B (en)	2018-01-26	2021-02-04	Univ Nova De Lisboa	ANTIBODY, FUNCTIONAL FRAGMENT OR PROBE OF THE SAME AGAINST TUMORAL ANTIGENS
IL300314A (en)	2020-10-08	2023-04-01	Affimed Gmbh	Trispecific binders
AU2022320948A1 (en)	2021-07-30	2024-01-18	Affimed Gmbh	Duplexbodies
EP4426439A1 (en)	2021-11-03	2024-09-11	Affimed GmbH	Bispecific cd16a binders
WO2025257588A1 (en)	2024-06-10	2025-12-18	Affimed Gmbh	Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989006692A1 (en) *	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
IL106992A (en) *	1988-02-11	1994-06-24	Bristol Myers Squibb Co	Acylhydrazone derivatives of anthracycline and methods for their preparation
US5705157A (en) *	1989-07-27	1998-01-06	The Trustees Of The University Of Pennsylvania	Methods of treating cancerous cells with anti-receptor antibodies
ZA9811162B (en) *	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
CA2357525A1 (en) *	1999-01-27	2000-08-03	Cornell Research Foundation, Inc.	Treating cancers associated with overexpression of her-2/neu
US6333348B1 (en) *	1999-04-09	2001-12-25	Aventis Pharma S.A.	Use of docetaxel for treating cancers
AU782325B2 (en) *	1999-05-14	2005-07-21	Genentech Inc.	Treatment with anti-ErbB2 antibodies

1999
- 1999-07-20 GB GBGB9917012.8A patent/GB9917012D0/en not_active Ceased
2000
- 2000-07-10 EP EP00945903A patent/EP1200098A2/en not_active Withdrawn
- 2000-07-10 WO PCT/EP2000/006540 patent/WO2001005425A2/en not_active Ceased
- 2000-07-10 JP JP2001510479A patent/JP2003504413A/en not_active Withdrawn
- 2000-07-10 AU AU59839/00A patent/AU5983900A/en not_active Abandoned

Also Published As

Publication number	Publication date
AU5983900A (en)	2001-02-05
WO2001005425A2 (en)	2001-01-25
JP2003504413A (en)	2003-02-04
WO2001005425A3 (en)	2001-05-17
EP1200098A2 (en)	2002-05-02

Publication	Publication Date	Title
GB9917012D0 (en)	1999-09-22	Combined preparations comprising antitumor agents
PL343096A1 (en)	2001-07-30	Sustained release preparations
MXPA02001508A (en)	2003-07-21	Arylmethylcarbonylaminothiazole derivatives and their use as antitumor agents.
GB9911863D0 (en)	1999-07-21	Therapeutic agents
GB9905010D0 (en)	1999-04-28	Therapeutic agents
AU2002224595A1 (en)	2002-02-13	Antitumor agents
GB9909925D0 (en)	1999-06-30	Combined preparations comprising anthracycline derivatives
GB9904786D0 (en)	1999-04-28	Therapeutic agents
EP1154755A4 (en)	2003-08-13	Liposome formulations
GB9911881D0 (en)	1999-07-21	Therapeutic agents
GB9903476D0 (en)	1999-04-07	Therapeutic agents
GB9926529D0 (en)	2000-01-12	Targeting agents
GB9914745D0 (en)	1999-08-25	Therapeutic agents
AU7446000A (en)	2001-04-30	Antitumor agents
HUP0200483A3 (en)	2004-07-28	Liposome preparations
GB9914744D0 (en)	1999-08-25	Therapeutic agents
GB9903119D0 (en)	1999-04-07	Therapeutic agents
GB9929801D0 (en)	2000-02-09	Anti-cancer agents iii
AU8252101A (en)	2002-03-13	Oct preparations
GB9914742D0 (en)	1999-08-25	Therapeutic agents
EP1201245A4 (en)	2005-01-12	Functional oral preparations
GB9902881D0 (en)	1999-03-31	Therapeutic agents
GB9914743D0 (en)	1999-08-25	Therapeutic agents
GB9915616D0 (en)	1999-09-01	Therapeutic agents
GB9918057D0 (en)	1999-10-06	Therapeutic agents

Legal Events

Date	Code	Title	Description
2000-11-01	AT	Applications terminated before publication under section 16(1)